BioSpace News Archive

Collaboration will integrate Microsoft Azure AI and Volastra’s insights into tumor biology to develop machine learning tools to detect drivers of tumor growth and predict metastatic risk

MediZap, North America’s leading turn-key service provider of e-beam terminal sterilization for compounded pharmaceuticals announces an exciting partnership with Analytical Lab Group, now part of Element Materials Technology, to offer sterile compounding testing services, analytical chemistry, and more to its pharmaceutical compounding clients.

Findings from an analysis of the first 500 patients enrolled in the SPHERE registry found more than three-quarters of pulmonary arterial hypertension patients treated with UPTRAVI® either maintained or reduced their one-year mortality risk score.

Valeo Pharma Inc . , a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin (“LMWH”) biosimilar, for the prevention and treatment of thromboembolic disorders.

Financing Co-led by HBM Healthcare Investments and Samsara BioCapital Food and Drug Administration Accepts Investigational New Drug Application for MLS-101 and Advances to Phase 2 Proof-of-Concept Clinical Trial

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar , M.D., as Chief Medical Officer.

Baebies , a growth-stage company developing innovative products to enable early disease detection and comprehensive diagnosis, today announced that the U.S. Food & Drug Administration (FDA) acknowledged the company’s Emergency Use Notification (EUN) for an RT-PCR test to detect SARS-CoV-2 on the FINDER ® 1.5 Instrument .

Lexaria Bioscience Corp. a global innovator in drug delivery platforms, will begin important new applied research and development study programs planned in 2021.

Lannett Company, Inc. (NYSE: LCI) (the “Company”) today announced that it intends to offer, subject to market conditions and other factors, $350 million aggregate principal amount of senior secured notes due 2026 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20 th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET.